Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016).
Anti-Bacterial Agents
/ therapeutic use
Community-Acquired Infections
/ drug therapy
Diterpenes
/ therapeutic use
Haemophilus Infections
/ drug therapy
Haemophilus influenzae
/ drug effects
Humans
Methicillin-Resistant Staphylococcus aureus
/ drug effects
Microbial Sensitivity Tests
Moraxella catarrhalis
/ drug effects
Moraxellaceae Infections
/ drug therapy
Pneumococcal Infections
/ drug therapy
Pneumonia, Bacterial
/ drug therapy
Polycyclic Compounds
/ therapeutic use
Staphylococcal Infections
/ drug therapy
Streptococcus pneumoniae
/ drug effects
Thioglycolates
/ therapeutic use
antimicrobial
community-acquired bacterial pneumonia
lefamulin
pleuromutilin
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
11
10
2018
accepted:
18
01
2019
pubmed:
24
1
2019
medline:
13
3
2020
entrez:
24
1
2019
Statut:
epublish
Résumé
Lefamulin, the first semisynthetic pleuromutilin antibacterial for intravenous and oral treatment of community-acquired bacterial pneumonia (CABP), and comparators were evaluated for
Identifiants
pubmed: 30670415
pii: AAC.02161-18
doi: 10.1128/AAC.02161-18
pmc: PMC6437505
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Diterpenes
0
Polycyclic Compounds
0
Thioglycolates
0
lefamulin
21904A5386
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2019 American Society for Microbiology.
Références
Hosp Pract (1995). 2017 Feb;45(1):1-8
pubmed: 28064542
Antimicrob Agents Chemother. 2017 Jan 24;61(2):
pubmed: 27855075
Sci Rep. 2016 Dec 13;6:39004
pubmed: 27958389
Thorax. 2012 Jan;67(1):71-9
pubmed: 20729232
J Antimicrob Chemother. 2015 Aug;70(8):2199-202
pubmed: 25921512
J Med Econ. 2013;16(6):809-19
pubmed: 23574431
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4407-11
pubmed: 27161634
J Antimicrob Chemother. 2016 Apr;71(4):1022-6
pubmed: 26747098
Postgrad Med. 2010 Mar;122(2):130-41
pubmed: 20203464
N Engl J Med. 2015 Jul 30;373(5):415-27
pubmed: 26172429
J Manag Care Pharm. 2009 Mar;15(2 Suppl):S5-11
pubmed: 19236135
Adv Ther. 2010 Oct;27(10):743-55
pubmed: 20799007
Eur Respir J. 2013 Sep;42(3):559-63
pubmed: 24000245
J Antimicrob Chemother. 2019 Apr 1;74(Suppl 3):iii19-iii26
pubmed: 30949704
Am Health Drug Benefits. 2013 Sep;6(8):494-503
pubmed: 24991378
J Antimicrob Chemother. 2012 May;67(5):1170-5
pubmed: 22287234
Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72
pubmed: 17278083
Expert Rev Respir Med. 2019 Feb;13(2):139-152
pubmed: 30596308
Cold Spring Harb Perspect Med. 2017 Jan 3;7(1):
pubmed: 27742734
J Antimicrob Chemother. 2019 Apr 1;74(Suppl 3):iii35-iii41
pubmed: 30949705
Antimicrob Agents Chemother. 2013 Sep;57(9):4489-95
pubmed: 23836172
Natl Vital Stat Rep. 2018 Jul;67(5):1-76
pubmed: 30248015